Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/8/2007


1.		Phase III Randomized Study of Immunotherapy with an Allogeneic Melanoma Vaccine plus Interferon Alfa vs Interferon Alfa Alone in Patients with Metastatic Malignant Melanoma (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CORIXA-2885-14 RIR-2885-14, YALE-HIC-8666, NCI-V96-0883, NCT00002767

Last Modified: 5/31/2007 First Published: 1/1/1999


2.		Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				BIOMIRA-STn-BR-104 NCI-V98-1489, NCT00003638

Last Modified: 1/13/2006


3.		Phase III Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate-Thickness, Node-Negative Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-9035 SWOG-9035

Last Modified: 7/1/1992


4.		Phase III Randomized Study of Melacine (Melanoma Cell Lysate Vaccine) vs Chemotherapy with DTIC/CDDP/BCNU/TMX in Patients with Disseminated Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over								RIR-91CO28-CC NCI-V92-0019, NCI-V92-0102

Last Modified: 8/15/2008 First Published: 1/1/2001


5.		Phase I/II Study of Photodynamic Therapy With Verteporfin and Detox-B Adjuvant in Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Over 18				Pharmaceutical / Industry				QLT-VFI-PDV-01 QLT-PHO-VFI-PDV-01, NCT00007969

Last Modified: 5/1/1998


6.		Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 75				Other				UNMC-04094 NCI-V94-0589

Last Modified: 11/1/1991


7.		Phase II Pilot Study of Vaccination with the Ganglioside GM2 Covalently Attached to Keyhole Limpet Hemocyanin plus the Immunological Adjuvant Detox in Patients with Completely Resected Stage III/IV Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age								MSKCC-91012 NCI-V91-0043

Last Modified: 4/1/1992


8.		Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age								MSKCC-91095 NCI-V91-0167

Last Modified: 4/20/2007


9.		Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-94-C-0096D NCI-T93-0152N, T93-0152, NCT00019006

Last Modified: 5/1/1992


10.		Phase I Study of IL-2/CTX and Autologous Tumor Cell Vaccines in the Treatment of Metastatic Renal Carcinoma and Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				URCC-3788M NCI-T88-0151D, T88-0151

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute